Avet Pharmaceuticals Inc.
Dr. Ernest Jones has extensive experience in supply chain management and pharmaceutical manufacturing. Dr. Ernest has held various roles in reputable companies such as Avet Pharmaceuticals Inc., Teva Pharmaceuticals, and Hospira. Dr. Jones has also been a member of the Supply Chain Advisory Board at RPI Lally School of Management and a contributing author for The Refractive Thinker. Dr. Ernest'sexpertise includes overseeing supply planning, organizational change management, capacity planning, and project management. Dr. Jones has a track record of successful leadership and a passion for innovation in the field of supply chain management.
Dr. Ernest Jones completed their education with a Doctor of Business Administration (DBA) degree in Management from Argosy University, which they attended from 2009 to 2013. Prior to that, they pursued a Master of Business Administration (MBA) with a specialization in International Management from Lake Forest Graduate School of Management between 2007 and 2009. Dr. Jones began their academic journey by obtaining a Bachelor of Science (BS) in Chemical Engineering from Rensselaer Polytechnic Institute, spanning from 1993 to 1999. Dr. Ernest'seducation history also includes attending Loyola Blakefield, an educational institution, in the year 1993. Unfortunately, no specific degree or field of study information is available for their time there.
This person is not in any offices
Avet Pharmaceuticals Inc.
Avet Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company engaged in the acquisition, licensing, development, marketing, sale and distribution of generic pharmaceutical products for the global prescription drug markets. Avet Pharmaceuticals provides high quality generic medicines that help patients and practitioners achieve affordable healthcare solutions. Our global supply chain network is built around centers of manufacturing and scientific excellence to provide you with the highest level of quality, safety, value and service in generics. Our drug portfolio consists of numerous products across a wide range of therapeutic categories, including: cardiovascular, oncology, metabolic disease, anti-infective, infusion and pain management. We are focused on widely utilized, established products as well as niche, high barrier-to-entry products that have limited competition and long life cycles.